Core Insights - The company reported a revenue of 1.865 billion yuan and a net profit of 1.093 billion yuan for the first three quarters of 2025, maintaining a high gross margin of 93.36% [1] - The company's cash balance reached 1.18 billion yuan, and trading financial assets amounted to 1.973 billion yuan, indicating strong liquidity [1] - Research and development (R&D) investment totaled 237 million yuan, a significant increase of 26.67% year-on-year, with R&D expenditure accounting for 12.73% of revenue [1] Group 1 - The company has expanded its product pipeline through continuous R&D investment, launching new products such as "Kekela" in May and obtaining approval for the hair health product minoxidil in September [1] - Several products are in the pipeline, including type A botulinum toxin, which is in the registration phase, and semaglutide injection, which is in clinical trials, laying the foundation for future product iterations [1] - A subsidiary successfully completed the filing of a new cosmetic raw material "Glycyrrhizin A" in October, marking the company's entry into the cosmetic raw material sector and transitioning towards a diversified international giant covering "medical + beauty" [1] Group 2 - The company has established a presence in the skincare sector with a clear strategy of "medical beauty transformation," launching multiple skincare brands such as "Aifuyuan," "Haitihufu," and "Haitixiongmao" to create new growth drivers [2] - To enhance global resource integration, the company completed the acquisition of 85% of South Korean REGEN Biotech, Inc., strengthening its position in the regenerative medical beauty sector and facilitating access to international sales channels [2]

Core Insights - Aimeike (300896) demonstrates strong resilience in a challenging industry environment, achieving revenue of 1.865 billion yuan and net profit of 1.093 billion yuan in Q3 2025, with a gross margin of 93.36% [1] Financial Performance - The company's core products, "Haitai" and "Rubai Angel," have established a dual moat of technological barriers and brand recognition, contributing to stable revenue and customer loyalty [1] - As of September 2025, Aimeike's cash reserves stood at 1.18 billion yuan, with a low debt-to-asset ratio of 8.20%, providing ample space for future R&D investments and strategic expansions [1] - The net cash flow from operating activities reached 1.073 billion yuan in the first three quarters, highlighting efficient working capital management [2] Shareholder Returns - Aimeike has implemented seven rounds of cash dividends since its IPO in 2020, totaling 3.887 billion yuan, reflecting management's confidence in long-term profitability [2] Strategic Initiatives - The company has increased R&D investment to 237 million yuan in the first three quarters of 2025, a 26.67% year-on-year increase, with R&D expenses accounting for 12.73% of revenue [2] - New product launches include "Kekola" for chin contouring and a minoxidil solution for hair health, expanding the product pipeline [3] - Aimeike's subsidiary has successfully registered a new cosmetic ingredient, marking its entry into the cosmetic raw materials sector [3] - The acquisition of 85% of South Korea's REGEN Biotech, Inc. enhances Aimeike's regenerative medicine offerings and opens international market channels [3] Industry Outlook - The medical beauty industry is expected to see increased differentiation, necessitating players to build high-profit resilience and maintain clear strategic layouts and robust pipeline reserves [4]

Investment Rating - The investment rating for the company is "Outperform the Market" [5][15][19] Core Views - The company's mid-year performance has been under pressure, with a revenue of 1.299 billion yuan, down 21.59% year-on-year, and a net profit attributable to shareholders of 789 million yuan, down 29.57% year-on-year. The second quarter alone saw a revenue of 636 million yuan, down 25.11% year-on-year, and a net profit of 346 million yuan, down 41.75% year-on-year [1][7] - The company has a rich product matrix in the medical beauty sector, which lays a foundation for long-term growth potential. The acquisition of an 85% stake in the South Korean company REGEN enhances its regenerative product offerings and opens up international market sales [2][9] - Despite a decrease in gross margin to 93.44%, the company continues to invest in research and development, with a research expense ratio of 12.05%, up 4.46 percentage points year-on-year [2][9] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 1.299 billion yuan, a decrease of 21.59% year-on-year, and a net profit of 789 million yuan, down 29.57% year-on-year. The second quarter's revenue was 636 million yuan, down 25.11% year-on-year, with a net profit of 346 million yuan, down 41.75% year-on-year [1][7] - The company distributed a cash dividend of 12 yuan per 10 shares, totaling 362 million yuan, which accounts for 45.82% of the net profit for the first half of the year [1][7] Product Development - The company’s revenue from solution-type injection products was 744 million yuan, down 23.79% year-on-year, while gel-type injection products generated 493 million yuan, down 23.99% year-on-year. The acquisition of REGEN is expected to strengthen its position in the regenerative medical beauty field [2][9] - The company is in the registration phase for its botulinum toxin products, which are expected to be launched soon, further enriching its product matrix [2][9] Financial Ratios and Projections - The gross margin for the first half of 2025 was 93.44%, a decrease of 1.48 percentage points year-on-year. The selling expense ratio and management expense ratio were 11.1% and 5.34%, respectively, both showing increases due to rigid costs and declining revenue [2][9] - The company has adjusted its net profit forecasts for 2025-2027 to 1.855 billion yuan, 2.073 billion yuan, and 2.325 billion yuan, respectively, with corresponding price-to-earnings ratios of 29.9, 26.8, and 23.9 [3][15]